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Abstract
Background Since 2014, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Mus-
culoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide.
Aim Based on this document, a Southeast Asia Working Group (SEAWG) wished to see how the new ESCEO algorithm 
developed in 2019 was perceived by Southeast Asian experts and how it was integrated into their clinical practice.
Methods A SEAWG was set up between members of the international ESCEO task force and a group of Southeast Asian 
experts.
Results Non-pharmacological management should always be combined with pharmacological management. In step 1, symp-
tomatic slow-acting drugs for osteoarthritis are the main background therapy, for which high-quality evidence is available 
only for the formulations of patented crystalline glucosamine sulfate and chondroitin sulfate. In step 2, oral NSAIDs are a 
useful option, considering the cardiovascular/renal/gastrointestinal profiles of the individual patient. Intra-articular hyalu-
ronic acid and corticosteroids are a possible alternative to oral NSAIDs, but limited evidence is available. If steps 1 and 2 
do not give adequate relief of symptoms, tramadol can be used, but its safety is debated. In general, the indications of the 
ESCEO algorithm are important in Southeast Asian countries, but the reimbursement criteria of local health systems are an 
important aspect for adherence to the ESCEO algorithm.
Conclusion This guidance provides evidence-based and easy-to-follow advice on how to establish a treatment algorithm in 
knee OA, for practical implementation in clinical practice in Southeast Asian countries.
Keywords Knee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for 
osteoarthritis · Algorithm
Introduction
Osteoarthritis (OA) is one of the most common joint dis-
eases in older people, mainly characterized by joint pain and 
stiffness with deep consequences on functional decline/dis-
ability and loss in quality of life [1, 2]. Knee OA is the most 
common localization within the symptomatic form affecting 
more than 250 million people worldwide [3]. Knee OA is 
ranked among the most common causes of global disability 
in terms of Disability-Adjusted Life Years (DALY) and poor 
quality of life [4–6].
In 2014, the European Society for Clinical and Economic 
Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal 
Diseases (ESCEO) published some recommendations for the 
management of knee OA, developing a treatment algorithm 
that may give practical guidance for the prioritization of 
interventions and guiding physicians through progressive 
steps [7]. However, since the publication of the 2014 algo-
rithm, new research has become available, with a particular 
attention to the safety of many medications commonly used 
to treat knee OA [8–11]. In 2016, as new observational data 
regarding drug safety became available, an update to the 
ESCEO algorithm was published [12].
Therefore, in 2019, a new algorithm [13] was published 
taking into account the recent evidence on efficacy and 
safety of medications commonly used for knee OA and 
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the GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) process was added, to better 
highlight the evidence used in the algorithm in a transparent 
and systematic way [14]. Since 2014, the ESCEO algorithm 
has been well-received worldwide and endorsed by many 
national societies with a consequent translation, adaptation 
to the local context, and publication in several countries 
including China, Russia, Central Europe and Southeast Asia 
[15–20]. For this reason, a working group (WG) was formed 
between members of the international ESCEO task force 
(N.V., J.M.K., and J.-Y.R.) and a group of Southeast Asian 
experts in knee OA (SEAWG) to see how Southeast Asian 
key opinion leaders perceive this algorithm and how it can 
be combined, with their own clinical practice, to harmonize 
and optimize the management of patients with knee OA 
throughout the world.
Non‑pharmacological treatment in the 2019 ESCEO 
algorithm
In the 2019 knee OA algorithm, non-pharmacological treat-
ments (information/education; weight loss if overweight; 
and an exercise program mixing aerobic and strengthening 
exercises) have a major importance and is supported by a 
high level of evidence according to GRADE [7, 13, 21], 
even if the effect of these interventions is limited and their 
feasibility in the long term is still debated [22]. The South-
east Asian experts, during the workshop, highlighted the 
importance of non-pharmacological interventions (such as 
education and weight loss), including the use of Tai-Chi [23] 
and acupuncture [24] in patients in their clinical practice, 
even if this evidence for these last two interventions is sup-
ported by low quality studies.
Pharmacological treatment in the 2019 
ESCEO algorithm
Step 1: background treatment
Paracetamol
Paracetamol (acetaminophen) is widely used for the treat-
ment of knee OA symptoms, even though in 2014 ESCEO 
reported that this medication has only a small effect on pain 
and no significant effect on stiffness and physical function 
in patients with knee OA [25–27]. During 2014–2018, sev-
eral concerns were available regarding safety over its rou-
tine chronic use, due to the increased risk of gastrointes-
tinal (GI), cardiovascular (CV), hepatic and renal adverse 
events (AEs) [28] and increased mortality [29]. Surpris-
ingly, even if paracetamol is widely used, its mechanism 
of action is not completely known, even if it is likely to 
involve cyclo‐oxygenase‐2 (COX‐2) inhibition, particularly 
when the cellular environment is low in arachidonic acid 
and peroxides such as in gastrointestinal and cardiovascular 
systems [30].
Based on this evidence (limited effect and increased risk 
of AEs), the 2019 ESCEO reccomends that paracetamol 
should be used only for short periods, as rescue medication 
when there is the inefficacy of the background therapy and 
at doses less than 3 g /day [13].
SYSADOAs
In both 2014 and 2019 versions of the ESCEO algorithm, 
Step 1 treatment of knee OA, recommends initiation of back-
ground therapy with long-term SYSADOAs (Symptomatic 
Slow-acting Drugs for Osteoarthritis) [7, 13], even if this 
class includes several products such as glucosamine, chon-
droitin, diacerein, and avocado soybean unsaponifiables 
(ASU), which are supported by varying degrees of clinical 
efficacy and safety data.
Glucosamine and chondroitin are natural compounds. 
Glucosamine hydrochloride (GHCl) is obtained by extrac-
tion processes and used as a nutraceutical or over-the counter 
(OTC) products. In contrast, glucosamine sulfate (GS) is 
a more sophisticated product, which can be obtained only 
by a proprietary semi-synthetic route and stabilization pro-
cess and that is used only in the prescription drug product, 
i.e. patented crystalline glucosamine sulfate (pCGS) [31]. 
Unfortunately, multiple formulations of GS are available 
[32], both as prescription-grade products and OTC, with 
the latter having small/varying amounts of glucosamine. 
On the contrary, there is extensive literature to suggest that 
only pCGS, at least at 1,500 mg per day, is able to deliver 
consistently high glucosamine bioavailability and plasma 
concentration in humans, which would result in good clini-
cal efficacy [33–40]. Conversely, GHCl and non-crystalline 
glucosamine sulfate products (usually consisting of GHCl 
with the addition of sodium sulfate to get a “sulfate” label-
ling) have consistently been shown to be ineffective in the 
treatment of knee OA [33, 35, 41–44]. A similar discussion 
can be applied to chondroitin sulfate [45–50].
Based on this scientific evidence, ESCEO specifically 
recommends the use of pCGS and long-acting chondroi-
tin sulfate products (the latter of which are not avail-
able in Southeast Asia) in both versions of 2014 and 
2019 of the algorithm [7, 13]. At the same time as the 
new ESCEO algorithm was released, another respected 
society, the Osteoarthritis Research Society International 
(OARSI) also updated their guidelines [51]. A working 
group recently conveyed by ESCEO examined the simi-
larities and differences between these two guidelines 
and provided a narrative document to help guide health-
care providers through the complexities of non-surgical 
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management of knee OA (reference enclosed to be added) 
[52]. Whereas many similarities between the two guide-
lines were observed, ESCEO strongly supports the use of 
pCGS and chondroitin sulfate, whereas OARSI does not 
support their use. The main reason for this discrepancy is 
that the OARSI guidelines, which were mainly prepared 
in a US-centric perspective, do not recognize the concept 
of “pharmaceutical-grade” or “prescription-grade” SYSA-
DOAs, such compounds being unavailable on the US soil 
[51][51].
The judgement of ESCEO is also based on the safety 
of SYSADOAs. Except for diacerein, several randomized 
placebo-controlled trials (RCTs) have demonstrated that 
SYSADOAs are not associated with any increased risk of 
AEs, both total and specific [11].
With regards to AEs, concerns have been raised regarding 
the safety of pCGS in patients with diabetes. Glucosamine, 
in fact, is an amino sugar that might lead to hyperglycemia 
and insulin resistance by over activating the hexosamine 
pathway [53]. However, it was already known that, once 
in plasma, glucosamine “does not go back to glucose”, but 
is directly catabolized and, therefore, no interference with 
glucose metabolism is expected [54]. This is also supported 
from the clinical trials’ data. At common doses used for 
OA treatment, pCGS showed no interference with glucose 
metabolism in normoglycemic subjects and in most sub-
jects with hyperglycemia, impaired insulin sensitivity, pre-
diabetes or diabetes [41, 55]. In addition, a meta-analysis 
on the effects of glucosamine on glucose metabolism found 
that glucosamine, at the usual oral doses used in knee OA 
patients, is well-tolerated by normal, diabetic, or pre-dia-
betic patients [56]. In the PROOF trial, a non-significant 
increase in glycated hemoglobin levels was found in over-
weight women who received pCGS during the follow-up 
period [57, 58]. Thus, the SEAWG recommends to advise 
caution at the start of treatment with glucosamine in diabetic 
patients [59].
Topical NSAIDs
At the last step of step 1 (background therapy), topical non-
steroidal anti-inflammatory drugs (NSAIDS) may be added 
as cyclic therapy if the patient is still symptomatic. Whilst 
there is sufficient evidence that these medications are safe 
[8], their efficacy has been only demonstrated in short-term 
RCTs and, therefore, more data are needed for giving these 
medications for longer periods [13]. The most recent algo-
rithm suggested that topical NSAIDs may be used in pref-
erence to oral NSAIDs, particularly in frail patients with 
knee OA, or prior to use of oral NSAIDs. The SEWG was 
in agreement with the use of topical NSAIDs for the control 
of persistent pain in knee OA.
Step 2: advanced pharmacological treatment
If the patient is still suffering from pain or has important 
limitations in the activities of daily living, step 2 of the 
updated version of the algorithm will commence. Step 2 
consists of two approaches.
The first approach is the use of oral NSAIDs. Based on 
the literature available, particularly regarding the safety of 
these medications [10], ESCEO, in the 2019 algorithm, 
makes a strong recommendation to the use of oral NSAIDs 
(selective or non-selective) as Step 2 therapy, but only if 
used intermittently and for as briefly as possible [13]. More-
over, the use of oral NSAIDs should be based on the patient 
risk profile, taking in consideration cardiovascular, renal, 
gastrointestinal co-morbidities [13]. Oral NSAIDs, in fact, 
should be not used in case of clinical forms of cardiovascular 
(e.g. decompensanted heart failure), renal (e.g. chronic renal 
failure with a creatinine clearance < 30 ml/min) or gastroin-
testinal (e.g. upper or lower gastrointestinal hemorrhages). 
When permitted it is important to remember that ESCEO 
recommended that all NSAIDs should be used at the lowest 
effective dose for the shortest period of time necessary to 
control pain [13]. Moreover, when using oral NSAIDs in 
older people, it is also important to consider the role of drug 
interaction in the development of adverse drug reaction. 
Drug-drug interactions (DDIs) in poly-therapy are one of the 
commonest causes of medication errors in geriatric medi-
cine, with an estimated prevalence of 20–40% [60]. When 
talking about oral NSAIDs, a nice study reported that these 
medications may act on MAP kinase (MAPK) signal trans-
duction pathway in the synovial membrane [61], a pathway 
that can be affected by the use of other medications [62].
The second part of step 2 consists of the use of intra-artic-
ular medications, i.e. hyaluronic acid and corticosteroids. 
For both these intra-articular products, there is weak evi-
dence that supports the use of hyaluronic acid and corticos-
teroids in those who cannot take oral NSAIDs. The reasons 
for this decision are based on inconclusive efficacy, higher 
risk of AEs when compared to placebo and only having shor-
term RCTs supporting the use of these drugs [9, 13].
The SEAWG agreed to the judicious use of NSAIDs for 
acute exacerbation of knee OA with inflammatory compo-
nent, after considering the patient profile and co-morbid 
conditions with reference to gastrointestinal, cardiac and 
renal diseases. The dose of NSAIDs should be the lowest 
effective dose.
Step 3: last pharmacological treatment
Last pharmacological options for the severely symptomatic 
patient are represented by short-term weak opioids. Trama-
dol may offer good analgesia in knee OA [63, 64], but a 
recent meta-analysis of the safety of oral opioids used in 
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OA found an increased risk of gastrointestinal, central nerv-
ous system, and dermatological AEs compared with placebo 
[65]. For this reason, ESCEO gives only a weak recommen-
dation to the use of short-term weak opioids in Step 3, as the 
last pharmacological option before surgery [13]. A similar 
evidence base is available for duloxetine [13].
The SEAWG concurs to the use of low dose weak opi-
oids, such as tramadol, with the needed precaution for their 
known adverse events of nausea, somnolence and vomiting.
Step 4: end‑stage disease management and surgery
Total knee replacement (TKR) is appropriate when all previ-
ous interventions have failed, if the patient is still sympto-
matic, and, in particular, when a significant loss in quality of 
life is present [66–68]. However, for symptomatic patients 
in whom surgery is cotraindicated, the last pharmacologi-
cal resort could be oral or transdermal opioids [69], which 
should be prescribed following the guidelines for use of opi-
oid analgesics in the management of non-cancer pain [70].
The SEAWG adds that background physical therapy is 
to be continued for surgery-averse patients or those where 
surgery is contraindicated.
Specificities of osteoarthritis management 
for Southeast Asia
As declared in the Introduction, the main objective of this 
paper is to find a consensus between experts from various 
South-East Asian countries and to offer a reference docu-
ment which takes into account the national specificities and 
tries to be also as consensual as possible with the document 
published by one non-South East Asian respected society.
As a group of Southeast Asian experts in OA manage-
ment, the SEAWG has carefully reviewed the ESCEO 
algorithm, including the most recent update of this year, 
considering it to be almost similar to the clinical practice 
pathways in several Southeast Asian countries. Therefore, 
as described in this paper, the WG endorses the principles 
of the ESCEO algorithm, reaching a consensus regarding 
recommendations for the stepwise multi-modal treatment 
of knee OA in Southeast Asia. With this work, of course, 
we cannot affirm to have included all the guidelines present 
in Southeast Asia countries and that these are in line to the 
ESCEO algorithm. Some national countries have indeed, 
significant differences in their guidelines compared to what 
is recommended in the ESCEO algorithm (e.g. the use of 
oral NSAIDs in the first and not in the second step of knee 
OA management), but that after an extensive discussion 
among the experts present at the meeting, we reached a for-
mal consensus and the experts co-signing this paper agreed 
to the ESCEO recommendations.
However, it should be recognized that, in clinical practice, 
treatment should be based upon the individualized assess-
ment of the patient, considering patients’ needs and prefer-
ences, the subjective interpretation of the evidence by the 
physician, and of course, subject to the local availability of 
a medication. In Southeast Asia, many countries acknowl-
edge the definitive treatment for severe OA to be surgical 
in the form of TKR and prevention to avoid this late stage 
is advocated by at least delaying disease progression with 
SYSADOAs. Not all SYSADOAs are available at pharmaco-
logical doses and, in Southeast Asia, may be included only 
OTC preparations for which the efficacy is still not clarified. 
Local practices and cultural variations employ traditional 
healing remedies without large-scale controlled clinical tri-
als. Complementary and alternative remedies in the form of 
endemic topical and aromatic preparations as well as physi-
cal manipulation (e.g. ayurveda or acupuncture) provides 
symptomatic relief among OA patient sufferers historically, 
even if limited data are available. These treatment modalities 
must be taken into consideration when planning out a com-
prehensive management approach for the patient. Adopting 
the ESCEO knee OA guidelines is a structured approached 
that is well-applicable in each of Southeast countries.
Another important point is that the criteria for reimburse-
ment, as well as the organization of the local health care 
system, significantly vary across Southeast Asian countries 
and this should be taken into consideration when choosing 
treatment options. Moreover, in the same country, there may 
be differences between rural and urban areas, for example, in 
terms of the availability of different pharmacological agents. 
Furthermore, not all SYSADOAs are reimbursable by the 
public health care systems and, in some cases, even if reim-
bursed, it is only for limited periods. For this specific rea-
son, the SEAWG wish to highlight the importance of health-
economic studies that should be done locally to increase 
the rate of reimbursement of pharmacological agents that 
can be used to reduce OA progression. At this stage, the 
ESCEO algorithm is mainly based on the scientific and clini-
cal evidence regarding efficacy and safety. [13] However, 
since the works regarding economic aspects are increasingly 
recognized as important, a future document including the 
health economics, with a specific application to the various 
South East Asian countries, could be an interesting work to 
be done.
In Southeast Asia, knee OA is a significant problem. For 
example, in the Philippines, almost 4 million people suf-
fer from this medical condition, but unfortunately it is not 
considered among those chronic conditions that should be 
addressed by specific public health programs. For this rea-
son, in 2017, a Philippine National OA Multidisciplinary 
Program was proposed to treat OA better. This multidis-
ciplinary approach took into consideration the indications 
and the steps given by the 2019 ESCEO algorithm [13]. The 
1153Aging Clinical and Experimental Research (2021) 33:1149–1156 
1 3
application of the Philippine OA Program does not differ in 
practice from the steps given in the ESCEO at core step and 
step 1, even if paracetamol is given as background therapy 
at low doses, In step 2, the WG noted that not all oral or 
topical NSAIDs are reimbursed by the Philippines health 
care. Overall, the Philippine experts strongly believe in the 
concepts of the 2019 ESCEO algorithm, highlighting the 
importance of education of health care workers and specialty 
referral for the most appropriate management of knee OA.
In Thailand, a recent consensus (Thai Consensus Confer-
ence on Pharmacological Management of Knee OA 2019) 
was held. The minutes of this meeting are freely available 
at this website: https:// www. thaih ipkne es. org/ infor mation/ 
manual- and- proce edings- of- the- thai- conse nsus- confe rence- 
on- pharm acolo gical- manag ement- of- knee- oa- 20192/. This 
consensus involved 69 experts in knee OA and was divided 
in two main parts, i.e. oral and non-oral/topical medications 
for knee OA management. Overall, a strong consensus was 
reached for the use of oral NSAIDs prescribed as the first-
line drug for knee OA, even if they should only be used for 
a short-term period and intermittently, with caution, and the 
patient’s comorbid conditions taken into account, avoiding 
the concomitant use of paracetamol. This consensus recog-
nized the importance of pCGS (and not OTC products) as 
first line/background therapy, which should be used con-
tinuously (if possible) and without any age restrictions. 
New research results were presented based on a real-life 
study using pCGS in Thailand. In the study, 250 Thai older 
people, with more than 50 years, with grade 2–3 KL knee 
OA were followed for 24 weeks and treated with 1500 mg/
day of pCGS. The results of this study showed that pain 
scores, as measured by the visual analogue scale signifi-
cantly improved after treatment with pCGS. In addition, this 
study also showed a positive effect of pCGS on quality of life 
(measured with short form 36) and physical performance, as 
measured with the timed up-and-go test. Despite the obser-
vational nature of these data, this study opens up the idea of 
a possible effect of pCGS on physical function and quality 
of life.
In Malaysia, knee pain is extremely common and often 
due to knee OA. In the Community Oriented Program for 
the Control of Rheumatic Diseases (COPCORD) survey, 
14.4% complained of pain in the joints and/or musculo-
skeletal pain. The knee site was responsible for about two/
thirds of all complaints pertaining to the joints, and more 
than half those examined with knee pain had clinical evi-
dence of OA [71]. In this country, knee pain is a common 
cause of presentation to the general practitioner, with one 
study showing it to be the 7th most common complaint. 
Due to the high frequency of knee pain and presumed OA 
in the community, a Malaysian Clinical Practice Guideline 
for the Management of OA was first published in 2002, 
with a second edition in 2013. For the future, the main 
aim would be to get health economic data assessing the 
economic burden of OA, and the cost-effectiveness of 
treatment with SYSADOAs.
Finally, Macau has about 636,000 inhabitants, with 
a long-expected mean life expectancy (about 86 years). 
Therefore, knee OA is a common condition in this country, 
representing about 15–50% of all orthopedic consultations. 
In Macau, the 2019 ESCEO algorithm is followed in all 
its steps. Regarding GS, its use was started in 1990 and 
now is available in different forms. Importantly, the Macau 
experts believe that pCGS is highly effective for knee OA 
symptomatology and that most old people like a simple 
once-daily dosage, even if many products (with different 
costs and effect on knee OA symptoms) are available in 
this country.
Conclusions
Knee OA is a signifcant problem in Southeast Asian coun-
tries, associated, similar to the rest of the world, with a 
high rate of disability and poor quality of life. In this 
paper, the WG has briefly summarized the reccomenda-
tions of the 2019 ESCEO algorithm and highlighted areas 
where it applies to clinical practice in Southeast Asia. 
Overall, the steps of the algorithm are followed and rec-
ognized as important, even if the different reimbursment 
criteria may change the way the algorithm is followed. 
This guidance provides evidence-based and easy-to-fol-
low advice on how to establish a treatment algorithm in 
patients with knee OA, for practical implementation in the 
Southeast Asian countries’ clinical practice.
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